Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Coiffier

Showing results (151-160 of 249) with videos related to

Pageof 25
Sort By:
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Blood|September 28, 2002
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcomePrzemyslaw Juszczynski, Ewa Kalinka, Jacques Bienvenu, et al.
British Journal of Haematology|July 9, 2002
Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA studyCharles Dumontet, Nicolas Mounier, Jean Nicolas Munck, et al.
The New England Journal of Medicine|March 25, 2005
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphomaFélix Reyes, Eric Lepage, Gérard Ganem, et al.
Blood|March 18, 2017
Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface areaCaroline Gay, Richard Delarue, Noel Milpied, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2006
Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosisHervé Ghesquières, Françoise Berger, Pascale Felman, et al.
British Journal of Haematology|April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trialRuth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Leukemia & Lymphoma|November 19, 2013
Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic managementCédric Rossi, Gabriel Brisou, Lucile Baseggio, et al.
Blood|August 12, 2006
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) studyJehan Dupuis, Jean-François Emile, Nicolas Mounier, et al.
Leukemia & Lymphoma|February 5, 2015
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trialLuis Fayad, Stephen M Ansell, Ranjana Advani, et al.
Pageof 25

Showing results (151-160 of 249) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myelomaJulie M Vose, Amit Panwalkar, Robert Belanger, et al.
Blood|September 28, 2002
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcomePrzemyslaw Juszczynski, Ewa Kalinka, Jacques Bienvenu, et al.
British Journal of Haematology|July 9, 2002
Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA studyCharles Dumontet, Nicolas Mounier, Jean Nicolas Munck, et al.
The New England Journal of Medicine|March 25, 2005
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphomaFélix Reyes, Eric Lepage, Gérard Ganem, et al.
Blood|March 18, 2017
Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface areaCaroline Gay, Richard Delarue, Noel Milpied, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2006
Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosisHervé Ghesquières, Françoise Berger, Pascale Felman, et al.
British Journal of Haematology|April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trialRuth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Leukemia & Lymphoma|November 19, 2013
Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic managementCédric Rossi, Gabriel Brisou, Lucile Baseggio, et al.
Blood|August 12, 2006
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) studyJehan Dupuis, Jean-François Emile, Nicolas Mounier, et al.
Leukemia & Lymphoma|February 5, 2015
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trialLuis Fayad, Stephen M Ansell, Ranjana Advani, et al.
Pageof 25